GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Blau Farmaceutica BLAU3.SA · BRL

Health Care · B3 · 🇧🇷 Brazil

Compare

9.18

+2.46%

Close of 9 Nov 2026, in BRL

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in BRL, from our data supplier.

FY2025

Revenue

BRL 1.70bn

FY2016FY2025

Net income

BRL 295.0m

FY2016FY2025

Free cash flow

−BRL 39.8m

FY2016FY2025

Shareholders' equity

BRL 2.27bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueBRL 1.70bnBRL 1.75bnBRL 1.37bnBRL 1.41bnBRL 1.37bnBRL 1.18bnBRL 977.5mBRL 782.2mBRL 617.7mBRL 430.9m
Gross profitBRL 652.5mBRL 658.8mBRL 490.3mBRL 667.9mBRL 665.9mBRL 556.0mBRL 430.1mBRL 338.3mBRL 280.4mBRL 179.4m
Research and developmentBRL 38.9mBRL 30.2mBRL 42.4mBRL 38.9mBRL 52.1mBRL 28.5mBRL 12.0mBRL 15.3mBRL 12.2mBRL 13.6m
Operating incomeBRL 329.7mBRL 341.8mBRL 211.5mBRL 449.9mBRL 456.9mBRL 388.9mBRL 301.3mBRL 204.7mBRL 163.1mBRL 66.1m
Net incomeBRL 295.0mBRL 217.2mBRL 249.8mBRL 363.4mBRL 325.2mBRL 254.3mBRL 200.2mBRL 123.3mBRL 103.1mBRL 32.3m
Diluted earnings per share0.991.221.412.041.811.371.250.840.700.18

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsBRL 3.64bnBRL 3.41bnBRL 3.05bnBRL 2.50bnBRL 2.33bnBRL 1.27bnBRL 738.4mBRL 594.2mBRL 366.0mBRL 315.7m
Cash and short-term investmentsBRL 615.1mBRL 492.9mBRL 407.3mBRL 643.6mBRL 922.8mBRL 214.3mBRL 159.1mBRL 112.9mBRL 13.2mBRL 10.2m
Total liabilitiesBRL 1.38bnBRL 1.26bnBRL 1.06bnBRL 681.1mBRL 693.2mBRL 1.05bnBRL 472.7mBRL 370.8mBRL 227.6mBRL 218.2m
DebtBRL 568.9mBRL 523.4mBRL 575.0mBRL 311.7mBRL 374.5mBRL 690.0mBRL 278.9mBRL 225.1mBRL 103.9mBRL 141.9m
Shareholders' equityBRL 2.27bnBRL 2.16bnBRL 2.00bnBRL 1.82bnBRL 1.64bnBRL 221.3mBRL 265.8mBRL 223.3mBRL 138.3mBRL 97.5m
Shares outstanding297m178m178m178m179m186m160m147m148m175m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsBRL 222.2mBRL 507.2mBRL 188.1mBRL 171.9mBRL 154.0mBRL 226.5mBRL 221.3mBRL 82.5mBRL 126.6mBRL 45.7m
Capital spending−BRL 262.0m−BRL 141.1m−BRL 115.0m−BRL 180.1m−BRL 177.8m−BRL 91.2m−BRL 13.5m−BRL 251,000−BRL 36.1m−BRL 14.6m
Free cash flow−BRL 39.8mBRL 366.1mBRL 73.1m−BRL 8.2m−BRL 23.8mBRL 135.3mBRL 207.8mBRL 82.3mBRL 90.6mBRL 31.1m
Dividends paid−BRL 82.0m−BRL 56.1m−BRL 66.2m−BRL 135.5m−BRL 104.1m−BRL 326.9m−BRL 117.8m−BRL 33.4m−BRL 43.4m−BRL 12.7m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueBRL 486.6mBRL 435.0mBRL 389.4mBRL 475.2mBRL 464.8mBRL 373.0mBRL 456.0mBRL 473.6m
Gross profitBRL 201.9mBRL 171.8mBRL 143.7mBRL 192.7mBRL 187.1mBRL 149.5mBRL 182.3mBRL 181.6m
Operating incomeBRL 111.4mBRL 85.7mBRL 53.3mBRL 91.6mBRL 108.4mBRL 114.3mBRL 100.5mBRL 113.6m
Net incomeBRL 53.4mBRL 39.8mBRL 36.3mBRL 104.4mBRL 63.4mBRL 90.9mBRL 57.8mBRL 70.5m
Diluted earnings per share0.230.170.120.350.210.310.330.40
Cash from operationsBRL 178.0mBRL 1.0mBRL 66.0mBRL 138.0mBRL 31.0mBRL 46.0mBRL 172.0mBRL 134.0m
Capital spending−BRL 30.0m−BRL 14.0m−BRL 93.0m−BRL 117.0m−BRL 148.0m−BRL 22.0m−BRL 54.0m−BRL 34.0m
Free cash flowBRL 148.0m−BRL 13.0m−BRL 27.0mBRL 21.0m−BRL 117.0mBRL 24.0mBRL 118.0mBRL 100.0m
Total assetsBRL 4.03bnBRL 3.57bnBRL 3.64bnBRL 3.62bnBRL 3.47bnBRL 3.43bnBRL 3.41bnBRL 3.24bn
Cash and short-term investmentsBRL 884.9mBRL 542.2mBRL 615.1mBRL 636.2mBRL 297.9mBRL 442.1mBRL 492.9mBRL 431.9m
DebtBRL 244.5mBRL 533.3mBRL 606.2mBRL 545.2mBRL 503.9mBRL 551.4mBRL 559.0mBRL 549.5m
Shareholders' equityBRL 2.33bnBRL 2.29bnBRL 2.27bnBRL 2.35bnBRL 2.27bnBRL 2.20bnBRL 2.16bnBRL 2.10bn

Financial ratios

Data as of 27 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin38.3%37.5%35.7%47.5%48.7%47.0%
Operating margin19.4%20.2%26.7%35.6%37.3%31.2%
Net margin17.3%12.4%18.2%25.8%23.8%21.5%
Return on equity13.0%10.0%12.5%19.9%19.9%114.9%
Return on assets8.1%6.4%8.2%14.5%14.0%20.0%
Free cash flow yield16.8%37.6%17.6%20.4%19.1%17.6%
Revenue growth-3.0%27.8%-2.4%3.0%15.6%20.9%
Earnings growth35.8%-13.1%-31.3%11.7%27.9%27.0%
Current ratio2.47x3.12x4.63x4.52x4.95x2.20x
Debt to equity0.25x0.24x0.29x0.16x0.22x3.12x
Equity ratio62.5%63.4%65.5%72.9%70.3%17.4%
Interest coverage4.40x5.67x9.75x13.84x16.89x20.62x
R&D as a share of sales2.3%1.7%3.1%2.8%3.8%2.4%
Buybacks as a share of market value-67.4%-0.0%0.1%0.9%3.6%-16.4%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue6.6%7.6%16.1%
Operating income-9.8%-3.2%19.6%
Net income-6.7%3.0%29.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin37.9%39.6%42.0%42.4%
Operating margin19.4%21.4%24.8%24.8%
Net margin14.8%18.0%19.4%18.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings10.98.39.09.915.4
Price to sales1.91.01.62.63.7

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 30 Sept 2026.

FY2026FY2025FY2024FY2023FY2022FY2021
Paid in the year0.2270.7880.280.3250.6540.203
  • 13-for-10 split · 6 Jan 2026

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.